Get the app
US › Healthcare

Henry Schein Inc (HSIC)

US · Healthcare · Medical Distribution

$86.38-0.70%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$3.46B
Revenue YoY
+6.7%
Net profit
$94.0M
Profit YoY
+9.3%
EPS
$1.27
EPS estimate
$1.22
Net margin
2.7%

EPS came in at 1.27 against a street estimate of 1.22 — a beat of 4.1%.

Key statistics

Market cap
$9.69B
P/E
24.8
Forward P/E
14.8
P/B
3.09
Book value
$28.21
EPS (TTM)
$3.43
52-week high
$92.18
52-week low
$61.95
50-day MA
$87.57
200-day MA
$80.48
Beta
0.84

Analyst view

Analysts rate Henry Schein Inc a buy (8 buy, 7 hold, 1 sell out of 16) with an average price target of $97.27.

From the latest earnings call · 2026-08-04

CONFIDENT Q2 beat driven by 4.6% organic growth and margin expansion. Raised FY26 EPS guidance to $5.29–$5.39 (6–8% growth). Value creation initiatives tracking to $125M run rate by year-end. Q2 2026 U.S. dental benefited from converting episodic buyers to active customers via prior-year promotions. International strength in Canada, Germany, Spain, U.K. U.S. medical solid despite point-of-care diagnostic headwinds; Home Solutions near double-digit growth. Analysts pressed on consumables growth drivers (price vs. volume persistence), valuation disconnect on value creation math, and specialty margin durability. Management clarified episodic-to-active conversion sustaining momentum, Q3/Q4 benefit timing, and premium-implant strength in Europe offsetting value-implant mix drag. 2026-08-04…

Full summary in the app.

Shareholding

Insiders
0.83%
Institutions
112.16%

Largest institutional holders

FundStake
Kohlberg Kravis Roberts & Co LP14.04%
FMR Inc6.78%
BlackRock Inc6.30%
Artisan Partners Limited Partnership5.80%
Vanguard Capital Management, LLC5.69%
JPMorgan Chase & Co3.90%
State Street Corp3.86%
Vanguard Portfolio Management, LLC3.71%

Recent filings & reports

DocumentDate
Board / officer change · Q4 2026
HEADLINE NUMBERS • Henry Schein announced a planned CFO transition. • Ronald N. South will remain Senior Vice President and Chief Financial Officer
2026-10-08
Material agreement · Q3 2026
HENRY SCHEIN, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company amended and restated its revolving credit facility on September 21, 2026 • Increase
2026-09-22
Quarterly report · Q2 2026
HENRY SCHEIN, INC. - 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Net Sales (Six Months): $6,826 million, up 6.5% from $6,408 million prior
2026-08-04
Results announced · Q3 2026
HENRY SCHEIN, INC. – Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Net Sales: $3.5 billion, up 6.7% vs Q2 2025 (4.6% internal g
2026-08-04
Board / officer change · Q3 2026
HENRY SCHEIN, INC. - 8-K SUMMARY HEADLINE NUMBERS • No financial results disclosed in this filing • This is a leadership transition announcement date
2026-07-30
Shareholder vote results · Q2 2026
HENRY SCHEIN, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held May 21, 2026 • Ten incumbent directors elected for terms exp
2026-05-22
Quarterly report · Q1 2026
HENRY SCHEIN, INC. - Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Net Sales Q1 2026: $3,368 million (vs. $3,168 million Q1 2025) — increase of $200
2026-05-05
Results announced · Q2 2026
HENRY SCHEIN Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q1 2026 total net sales: $3.4 billion, up 6.3% versus Q1 2025 • Q1 2026 GAAP diluted EPS:
2026-05-05

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Henry Schein Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-10-19.